Barbour, Sean J

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Cherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 283

Lipoprotein Glomerulopathy, First Case Report from Canada

Ting, J. A., McRae, S. A., Schwartz, D., Barbour, S. J., & Riazy, M. (2022) · International Journal of Nephrology and Renovascular Disease

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 7

Individualised treatment effects of corticosteroids in IgA nephropathy

Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 2

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 1